Published • loading... • Updated
mRNA technology powers a better flu shot and what's behind those restless legs
The shot showed broader protection across age groups and strains, while the FDA is set to rule on approval by Aug. 5.
- An experimental mRNA flu vaccine cuts confirmed illness by about 27 percent compared to standard-dose shots, with The Food and Drug Administration expecting to decide on approval by August 5th.
- The same mRNA technology behind COVID-19 vaccines powers this flu shot development, potentially transforming annual immunization strategies.
- Protection holds across age groups, strains, and underlying health conditions, with particular benefit for adults 65 and older who face the greatest risk from flu complications.
- Side effects are slightly more common than standard shots, including injection site pain and fatigue, though most reactions are mild and short-lived.
- Researchers expect this advancement to reshape preventive care if approved, positioning mRNA technology as a cornerstone of next-generation vaccine development.
Insights by Ground AI
14 Articles
14 Articles
Krem2 News+13 Reposted by 13 other sources
mRNA technology powers a better flu shot and what's behind those restless legs
A new flu vaccine, a surprising discovery about mice that sing and the sleep condition affecting 30 million Americans — here's today's health news.
·Spokane, United States
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left2Leaning Right0Center12Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium
